Quanterix reported strong Q4 2025 revenue growth of 25% year-over-year, reaching $43.9 million, driven by product sales. Despite a decline in gross margins due to acquisition-related impacts, the company is progressing toward its goal of cash flow breakeven in 2026 following the integration of Akoya Biosciences.

Quanterix delivered 12.3% revenue growth in Q3 2025, driven by product sales, but posted a larger net loss due to acquisition, integration, and restructuring costs. Despite this, the company continued executing integration milestones from its Akoya acquisition and reiterated its full-year revenue outlook.

Quanterix experienced a challenging second quarter in 2025, with total revenue decreasing by 29% year-over-year to $24.5 million and a net loss of $30.0 million, significantly wider than the $7.4 million loss in the prior year. Despite these financial setbacks, the company completed the acquisition of Akoya Biosciences and made progress on cost reduction targets, aiming for cash flow breakeven in 2026.

Quanterix reported Q1 2025 revenue of $30.3 million, a 5% decrease year-over-year, and a net loss of $20.5 million, wider than the prior year. The company announced strategic initiatives, including a new Simoa ONE assay kit compatible with existing flow cytometers to expand market reach, and cost reduction measures targeting $30 million in annual savings to achieve positive cash flow by 2026. They also provided full-year 2025 revenue guidance of $120 million to $130 million.

Quanterix achieved 11% year-over-year revenue growth in Q4 2024, reaching $35.2 million. However, net loss widened to $11.6 million, driven by increased operating expenses. The company continues to expand into immunology and oncology markets while advancing its planned acquisition of Akoya Biosciences. Adjusted gross margin improved to 57.7% from 54.7% in the prior year, reflecting stronger operational efficiency.

Quanterix announced preliminary financial results for Q3 2024, achieving its sixth consecutive quarter of double-digit growth with a revenue of $35.7 million, a 13% increase compared to the prior year, and reaffirmed its full year 2024 revenue guidance of $134 million to $138 million. The company also disclosed the need to restate certain prior period financial statements.

Quanterix reported a 10.8% increase in revenue to $34.4 million for Q2 2024, driven by strong performance in the research business and a 35% increase in Accelerator service revenue. However, the company's net loss increased to $9.5 million, and GAAP gross margin decreased to 58.3%. The company ended the quarter with $299.5 million in cash and cash equivalents.

Quanterix reported a 12.7% increase in revenue to $32.1 million for Q1 2024 compared to the prior year period. The company's net loss increased to $10.1 million, and net cash usage for the quarter was $19.4 million. They ended the quarter with $304.5 million in cash, cash equivalents, marketable securities, and restricted cash.

Quanterix rescheduled its Q4 2023 earnings call and expects its 2023 revenue, gross margin, and cash usage to align with previous guidance.

Quanterix reported an 18% increase in revenue to $31.3 million and improved gross margins in Q3 2023. The company launched the LucentAD p-Tau 217 blood-based test for Alzheimer's disease and increased full-year revenue expectations.

Quanterix reported a 32% increase in total revenue to $31.0 million compared to the prior year's second quarter, with a GAAP gross margin of 61.7%. The company's net loss significantly decreased to $6.1 million, and net cash flow was approximately break-even.

Quanterix reported a decrease in revenue by 4% compared to Q1 2022, driven by a decline in instrument revenue, while net loss decreased by 66%. The company saw strong quarter-over-quarter improvement in gross margin and launched a new NfL LDT to expand its lab developed test menu.

Quanterix announced its Q4 2022 financial results, revealing that its revenue was in line with expectations following the strategic business realignment initiated in August 2022. The company saw strong quarter-over-quarter improvement in gross margin.

Quanterix reported its Q3 2022 results with revenue flat compared to the prior year, excluding RADx. The company's proforma gross margin decreased due to increased inventory reserves and changes in expense allocation. A restructuring and business re-alignment plan was announced in August 2022 to enhance the potential of Simoa platforms.

Quanterix reported that second quarter revenues were impacted by a reduction in consumable revenue due to assay quality challenges and process improvement initiatives. The company is implementing a strategic business re-alignment plan, including a workforce reduction of approximately 130 employees, to improve its cost structure and focus on key platforms.

Quanterix Corporation announced financial results for the first quarter of 2022, with revenue in line with expectations but gross margin falling short. The company is implementing changes to improve gross margins.

Quanterix reported strong third-quarter results driven by significant growth in consumables and instruments. The company is making progress in neurology and infectious disease with recent FDA designations.

Quanterix reported Q2 2021 GAAP revenue of $25.4 million and non-GAAP revenue of $24.4 million, representing an 86% increase over the prior year. Instrument placements also increased by 71%.

Quanterix reported Q1 2021 GAAP revenue of $27.2M. Non-GAAP revenue was $24.9M, representing a 58% increase compared to the prior year. The company is focused on innovating its technology and expanding its assay menu, particularly for early detection plasma biomarkers for Alzheimer's and neuro-degeneration.

Quanterix reported Q4 GAAP revenue of $26.1 million and non-GAAP revenue of $21.6 million, representing a 36% increase compared to the previous year. The company is focusing on the long-term impact of COVID-19 on human health and scaling its operations to meet the growing demand for ultra-sensitive protein analytical tools.

Quanterix announced financial results for Q3 2020, highlighting a strong quarter of growth despite pandemic-related headwinds. The company launched new Neurology assays, secured an NIH contract for SARS-CoV-2 Antigen test development, entered a non-exclusive IVD license agreement with Abbott, initiated surveillance studies, and raised nearly $100 million in capital.

Quanterix reported a strong second quarter, exceeding expectations despite challenges from the coronavirus pandemic. The company has been quick to respond to the crisis with critical testing advances and has made gains in neurology.

Quanterix Corporation reported strong Q4 2019 financial results, marking its ninth consecutive quarter of strong performance since going public. The company saw significant growth and technology adoption, particularly with its Simoa technology for measuring novel biomarkers.